Sign up USA
Proactive Investors - Run By Investors For Investors

Viking Thereapeutics soars on results of liver disease study

"The preliminary findings suggesting the potential triglyceride-lowering activity of VK2809 in GSD Ia are encouraging," said Professor Dwight Koeberl of Duke University School of Medicine.
Middle-age spread can lead to fatty liver disease

The value of Viking Therapeutics Inc (NASDAQ:VKTX) increased by one-sixth in pre-market trading after it unveiled positive results from a proof of concept study.

The clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders announced positive initial results from a proof-of-concept study of VK2809 on a remedy for a liver condition known as GSD Ia.

Data to date showed that treatment with VK2809 produced rapid and substantial reductions in liver triglyceride content, liver weight and liver weight as a percentage of body weight compared with standard treatments.

"These initial proof-of-concept data showing VK2809's activity in this model of GSD Ia are very encouraging. Due to its unique liver-targeted activity, we believe that VK2809 has a therapeutic profile that may align well with the treatment goal of reducing triglycerides, steatosis, and mitigating the metabolic complications of GSD Ia," said Brian Lian, Ph.D., chief executive officer of Viking. 

"GSD Ia is a rare metabolic disease for which there are no approved therapeutics. These patients suffer from a range of serious consequences, including an increased risk of liver bleeding, transplant, or cancer.  Our work in this area represents a strategic and complementary addition to our ongoing VK2809 development program, which currently includes a Phase 2 clinical trial in patients with hypercholesterolemia and non-alcoholic fatty liver disease," Lian said.

Shares in Viking were up 26 cents to US$1.83 in screen-based trading ahead of the official market open.


Register here to be notified of future VKTX Company articles
View full VKTX profile

Viking Therapeutics Timeline

Related Articles

September 20 2016
The absence of a discount suggests there is a healthy appetite for the equity.
November 20 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Blood test
September 27 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC